Kirk Binns - Medipharm Labs Ex Accounts
| MEDIF Stock | USD 0.05 0 2.22% |
Insider
Kirk Binns is Ex Accounts of Medipharm Labs Corp
| Phone | 705 719 7425 |
| Web | https://www.medipharmlabs.com |
Medipharm Labs Management Efficiency
The company has return on total asset (ROA) of (0.236) % which means that it has lost $0.236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5658) %, meaning that it generated substantial loss on money invested by shareholders. Medipharm Labs' management efficiency ratios could be used to measure how well Medipharm Labs manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sonny Newman | C21 Investments | N/A | |
| Cory Pala | Charlottes Web Holdings | N/A | |
| Luis Merchan | Flora Growth Corp | 43 | |
| Andres Gortari | Charlottes Web Holdings | 47 | |
| Eric Shoemaker | C21 Investments | N/A | |
| Matthew Cohen | Flora Growth Corp | 58 | |
| Patricia Colvin | Bionoid Pharma | N/A | |
| CPA CPA | Flora Growth Corp | N/A | |
| Kelly Shea | Charlottes Web Holdings | N/A | |
| Stephen Rogers | Charlottes Web Holdings | 57 | |
| Jacques Tortoroli | Charlottes Web Holdings | 64 | |
| Richard Mohr | Charlottes Web Holdings | 63 | |
| James Choe | Flora Growth Corp | 45 | |
| Perry Antelman | Charlottes Web Holdings | 59 | |
| Tim Orr | Charlottes Web Holdings | N/A | |
| FCA FCA | Flora Growth Corp | 79 | |
| Jared Stanley | Charlottes Web Holdings | 35 | |
| Greg Gould | Charlottes Web Holdings | N/A | |
| Javier Franco | Flora Growth Corp | 56 | |
| Jessie Casner | Flora Growth Corp | 36 | |
Management Performance
| Return On Equity | -0.57 | |||
| Return On Asset | -0.24 |
Medipharm Labs Corp Leadership Team
Elected by the shareholders, the Medipharm Labs' board of directors comprises two types of representatives: Medipharm Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medipharm. The board's role is to monitor Medipharm Labs' management team and ensure that shareholders' interests are well served. Medipharm Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medipharm Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keith Strachan, President Director | ||
| Greg Hunter, Chief Officer | ||
| Saravan Subramaniam, VP Chain | ||
| Nigel Dewsbury, Head Quality | ||
| Geoffrey Marr, Exec Counsel | ||
| Patrick McCutcheon, Founder | ||
| Brett Moon, VP Sales | ||
| Kirk Binns, Ex Accounts | ||
| David Pidduck, CEO Director |
Medipharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Medipharm Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.57 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (2.07) % | |||
| Operating Margin | (1.61) % | |||
| Current Valuation | 3.05 M | |||
| Shares Outstanding | 280.51 M | |||
| Shares Owned By Insiders | 3.92 % | |||
| Shares Owned By Institutions | 7.05 % | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 0.69 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Medipharm OTC Stock
Medipharm Labs financial ratios help investors to determine whether Medipharm OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.